Goldman Sachs initiates Schrodinger stock with Neutral rating, $19 price target

Schrodinger (SDGR) garnered mixed analyst attention, with Goldman Sachs initiating coverage with a Neutral rating and $19 price target, citing limited growth visibility for its core software business despite strong financials, while Barclays initiated with an Overweight rating and $25 target. The company reported a Q2 2025 net loss of $0.65 per share and revenue of $54.8 million, both exceeding analyst expectations. However, Schrodinger also announced the discontinuation of its CDC7 inhibitor SGR-2921 Phase 1 clinical program due to two treatment-related deaths, raising concerns about its drug discovery pipeline despite ongoing progress with other candidates.

Analysis

Schrodinger (SDGR) presents a bifurcated investment narrative, reflected in recent divergent analyst initiations. While Barclays initiated with an Overweight rating and a $25.00 price target, Goldman Sachs took a more cautious stance with a Neutral rating and a $19.00 target. Goldman's caution stems from limited visibility on future growth for the core software business, despite acknowledging the company's strong financial health, exemplified by a current ratio of 3.3 and more cash than debt. Operationally, Schrodinger surpassed Q2 2025 expectations with revenue of $54.8 million against a $52.02 million projection and a net loss of $0.65 per share, which was narrower than the anticipated $0.80 loss. However, this positive operational performance is significantly overshadowed by a major clinical setback: the discontinuation of its SGR-2921 Phase 1 study following two treatment-related deaths. This event raises material concerns about the safety and development risk within its proprietary drug discovery pipeline. The market's attention now shifts to upcoming catalysts, particularly initial Phase 1 data for SGR-3515 in solid tumors expected in the fourth quarter, which will be a crucial test for the pipeline's future. The stock's high volatility, indicated by a beta of 1.79, underscores the heightened risk profile stemming from these conflicting developments.

Key Decisions for Investors

• Investors should weigh the company's strong balance sheet and recent earnings beat against the significant clinical development risk highlighted by the SGR-2921 program's discontinuation.
• The upcoming initial Phase 1 data for SGR-3515 in Q4 should be considered a critical catalyst; a positive outcome could help restore confidence in the drug discovery pipeline, while a negative one would amplify existing concerns.
• Monitor future management commentary for progress on increasing customer utilization and growing annual contract values for the core software business, as this addresses the key visibility concerns cited by Goldman Sachs.
• Given the high volatility (beta of 1.79) and conflicting signals, risk-averse investors may consider waiting for further clinical data before initiating a new position.